Zamvil SS - Search Results

1

Moseley CE, Virupakshaiah A, Forsthuber TG, Steinman L, Waubant E, Zamvil SS. Moseley CE, et al. Among authors: zamvil ss. Neurol Neuroimmunol Neuroinflamm. 2024 Sep;11(5):e200275. doi: 10.1212/NXI.0000000000200275. Epub 2024 Jul 12. Neurol Neuroimmunol Neuroinflamm. 2024. PMID: 38996203 Free PMC article. Review.

2

Cholesterol-lowering statins possess anti-inflammatory activity that might be useful for treatment of MS.

Zamvil SS, Steinman L. Zamvil SS, et al. Neurology. 2002 Oct 8;59(7):970-1. doi: 10.1212/wnl.59.7.970. Neurology. 2002. PMID: 12370448 No abstract available.

3

The HMG-CoA reductase inhibitor, atorvastatin, promotes a Th2 bias and reverses paralysis in central nervous system autoimmune disease.

Youssef S, Stüve O, Patarroyo JC, Ruiz PJ, Radosevich JL, Hur EM, Bravo M, Mitchell DJ, Sobel RA, Steinman L, Zamvil SS. Youssef S, et al. Among authors: zamvil ss. Nature. 2002 Nov 7;420(6911):78-84. doi: 10.1038/nature01158. Nature. 2002. PMID: 12422218

4

Diverse targets for intervention during inflammatory and neurodegenerative phases of multiple sclerosis.

Zamvil SS, Steinman L. Zamvil SS, et al. Neuron. 2003 Jun 5;38(5):685-8. doi: 10.1016/s0896-6273(03)00326-x. Neuron. 2003. PMID: 12797954 Free article. Review.

5

Approved and future pharmacotherapy for multiple sclerosis.

Stüve O, Cree BC, von Büdingen HC, Yousef S, Bowen JD, Genain CP, Hauser SL, Steinman L, Zamvil SS. Stüve O, et al. Among authors: zamvil ss. Neurologist. 2002 Sep;8(5):290-301. doi: 10.1097/00127893-200209000-00002. Neurologist. 2002. PMID: 12803676

6

Statins as potential therapeutic agents in neuroinflammatory disorders.

Stüve O, Youssef S, Steinman L, Zamvil SS. Stüve O, et al. Among authors: zamvil ss. Curr Opin Neurol. 2003 Jun;16(3):393-401. doi: 10.1097/01.wco.0000073942.19076.d1. Curr Opin Neurol. 2003. PMID: 12858078 Review.

7

Statins and their potential targets in multiple sclerosis therapy.

Stüve O, Prod'homme T, Slavin A, Youssef S, Dunn S, Steinman L, Zamvil SS. Stüve O, et al. Among authors: zamvil ss. Expert Opin Ther Targets. 2003 Oct;7(5):613-22. doi: 10.1517/14728222.7.5.613. Expert Opin Ther Targets. 2003. PMID: 14498824 Review.

8

Statins as potential therapeutic agents in multiple sclerosis.

Stüve O, Prod'homme T, Youssef S, Dunn S, Neuhaus O, Weber M, Hartung HP, Steinman L, Zamvil SS. Stüve O, et al. Among authors: zamvil ss. Curr Neurol Neurosci Rep. 2004 May;4(3):237-44. doi: 10.1007/s11910-004-0044-2. Curr Neurol Neurosci Rep. 2004. PMID: 15102350 Review.

9

Virtues and pitfalls of EAE for the development of therapies for multiple sclerosis.

Steinman L, Zamvil SS. Steinman L, et al. Among authors: zamvil ss. Trends Immunol. 2005 Nov;26(11):565-71. doi: 10.1016/j.it.2005.08.014. Epub 2005 Sep 8. Trends Immunol. 2005. PMID: 16153891 Review.

10

Isoprenoids determine Th1/Th2 fate in pathogenic T cells, providing a mechanism of modulation of autoimmunity by atorvastatin.

Dunn SE, Youssef S, Goldstein MJ, Prod'homme T, Weber MS, Zamvil SS, Steinman L. Dunn SE, et al. Among authors: zamvil ss. J Exp Med. 2006 Feb 20;203(2):401-12. doi: 10.1084/jem.20051129. Epub 2006 Feb 13. J Exp Med. 2006. PMID: 16476765 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

233 results

Search Page

Filters